JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

JPMorgan Chase & Co. boosted its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 347.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 433,265 shares of the company’s stock after acquiring an additional 336,516 shares during the period. JPMorgan Chase & Co. owned 0.15% of Lyell Immunopharma worth $277,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Lyell Immunopharma by 43.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company’s stock worth $1,053,000 after purchasing an additional 498,417 shares during the period. Jane Street Group LLC raised its stake in shares of Lyell Immunopharma by 63.7% in the third quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock valued at $397,000 after buying an additional 111,917 shares during the period. Barclays PLC lifted its position in shares of Lyell Immunopharma by 312.7% during the 3rd quarter. Barclays PLC now owns 240,615 shares of the company’s stock valued at $332,000 after buying an additional 182,315 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Lyell Immunopharma by 102.8% during the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after acquiring an additional 59,182 shares during the period. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Stock Down 1.9 %

LYEL stock opened at $0.46 on Friday. Lyell Immunopharma, Inc. has a twelve month low of $0.39 and a twelve month high of $2.88. The firm has a market capitalization of $136.21 million, a PE ratio of -0.58 and a beta of -0.26. The stock has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.71.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Insider Activity at Lyell Immunopharma

In other Lyell Immunopharma news, CFO Charles W. Newton acquired 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $0.56 per share, with a total value of $112,000.00. Following the completion of the acquisition, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard Klausner acquired 158,000 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The stock was bought at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the completion of the transaction, the director now owns 843,365 shares of the company’s stock, valued at $506,019. The trade was a 23.05 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 768,640 shares of company stock valued at $449,508. Company insiders own 25.10% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.